CN1344270A - 作为趋化因子受体调节剂的官能化杂环 - Google Patents

作为趋化因子受体调节剂的官能化杂环 Download PDF

Info

Publication number
CN1344270A
CN1344270A CN99816475A CN99816475A CN1344270A CN 1344270 A CN1344270 A CN 1344270A CN 99816475 A CN99816475 A CN 99816475A CN 99816475 A CN99816475 A CN 99816475A CN 1344270 A CN1344270 A CN 1344270A
Authority
CN
China
Prior art keywords
methyl
quinolizine
chromene
decahydro
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99816475A
Other languages
English (en)
Chinese (zh)
Inventor
G·C·哈里曼
C·N·科尔兹
J·R·卢利
B·D·罗斯
Y·宋
B·K·特里维迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THOUSAND YEARS MEDICAMENTS Inc
Original Assignee
THOUSAND YEARS MEDICAMENTS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THOUSAND YEARS MEDICAMENTS Inc filed Critical THOUSAND YEARS MEDICAMENTS Inc
Publication of CN1344270A publication Critical patent/CN1344270A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN99816475A 1999-01-13 1999-12-20 作为趋化因子受体调节剂的官能化杂环 Pending CN1344270A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11565499P 1999-01-13 1999-01-13
US60/115,654 1999-01-13

Publications (1)

Publication Number Publication Date
CN1344270A true CN1344270A (zh) 2002-04-10

Family

ID=22362668

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99816475A Pending CN1344270A (zh) 1999-01-13 1999-12-20 作为趋化因子受体调节剂的官能化杂环

Country Status (20)

Country Link
EP (1) EP1144415A2 (ko)
JP (1) JP2002534526A (ko)
KR (1) KR20010086166A (ko)
CN (1) CN1344270A (ko)
AP (1) AP2001002228A0 (ko)
AU (1) AU1940900A (ko)
BR (1) BR9916905A (ko)
CA (1) CA2372197A1 (ko)
CZ (1) CZ20012502A3 (ko)
EA (1) EA200100774A1 (ko)
HK (1) HK1044539A1 (ko)
HU (1) HUP0202932A3 (ko)
IL (1) IL144289A0 (ko)
MX (1) MXPA01007033A (ko)
NO (1) NO20013456L (ko)
OA (1) OA11820A (ko)
PL (1) PL349348A1 (ko)
SK (1) SK9972001A3 (ko)
WO (1) WO2000042045A2 (ko)
ZA (1) ZA200106592B (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193669A (zh) * 2014-08-01 2014-12-10 大连理工大学 一类阿比朵尔类似物或其盐、其制备方法及应用
CN110256324A (zh) * 2019-06-13 2019-09-20 苏州莱安医药化学技术有限公司 一种2-甲基-5-羟基吲哚的制备方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072549A1 (en) * 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
DK1379239T3 (da) 2001-03-29 2008-01-07 Lilly Co Eli N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
WO2003035650A1 (fr) * 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Inhibiteur d'entree
MXPA05009771A (es) 2003-03-14 2005-10-26 Ono Pharmaceutical Co Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo.
WO2004092169A1 (ja) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
WO2006129679A1 (ja) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JP5251127B2 (ja) 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
CN101460458A (zh) 2006-02-15 2009-06-17 阿勒根公司 具有1-磷酸-鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚-3-羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
BRPI0707873A2 (pt) * 2006-02-15 2011-05-10 Allergan Inc compostos amida, Éster, tioamida e tiol Éster do Ácido indol-3-carboxÍlico carregando grupos arila ou heteroarila tendo atividade biolàgica antagonista de recptor de esfingosina-1-fosfato (s1p)
BRPI0708731A2 (pt) 2006-03-10 2011-06-07 Ono Pharmaceutical Co derivado heterocìclico nitrogenado, e agente farmacêutico compreendendo o derivado como ingrediente ativo
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
US8329689B2 (en) 2006-05-23 2012-12-11 Alexandre Vasilievich Ivachtchenko Substituted indoles and a method for the production and use thereof
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
CN101668741A (zh) 2007-01-11 2010-03-10 阿勒根公司 具有鞘氨醇-1-磷酸(s1p)受体拮抗剂生物学活性的6-取代吲哚-3-羧酸酰胺化合物
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
CN102958927A (zh) 2010-05-12 2013-03-06 Abbvie公司 激酶的吲唑抑制剂
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
WO2016112088A1 (en) * 2015-01-06 2016-07-14 Spero Therapeutics, Inc. Aryloxyacetylindoles and analogs as antibiotic tolerance inhibitors
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549641A (en) * 1966-06-28 1970-12-22 Warner Lambert Pharmaceutical Pyrano pyridines and process for their production
US3518258A (en) * 1967-05-09 1970-06-30 Warner Lambert Pharmaceutical Pyrano(3,2-i)quinolizine and process for the production
US3565903A (en) * 1967-11-24 1971-02-23 Warner Lambert Pharmaceutical Pyrano(2,3-b)quinolines and process for their production
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
HRP960352A2 (en) * 1996-07-26 1998-08-31 Pliva Pharm & Chem Works Novel coumarin quinoline carboxylic acids
BR9807858A (pt) * 1997-02-26 2000-02-22 Pfizer Derivados de amida do ácido heteroaril-hexanóico, suas preparaçÊes e seus usos como inibidores seletios de mip-1.alfa ligando aos seus receptores ccr1
CA2319781A1 (en) * 1998-02-02 1999-08-05 Liping Wang Cyclic amine modulators of chemokine receptor activity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193669A (zh) * 2014-08-01 2014-12-10 大连理工大学 一类阿比朵尔类似物或其盐、其制备方法及应用
CN110256324A (zh) * 2019-06-13 2019-09-20 苏州莱安医药化学技术有限公司 一种2-甲基-5-羟基吲哚的制备方法

Also Published As

Publication number Publication date
OA11820A (en) 2005-08-17
KR20010086166A (ko) 2001-09-08
JP2002534526A (ja) 2002-10-15
AU1940900A (en) 2000-08-01
HK1044539A1 (zh) 2002-10-25
NO20013456L (no) 2001-09-12
AP2001002228A0 (en) 2001-09-30
NO20013456D0 (no) 2001-07-12
WO2000042045A2 (en) 2000-07-20
EP1144415A2 (en) 2001-10-17
CZ20012502A3 (cs) 2002-03-13
MXPA01007033A (es) 2003-07-21
EA200100774A1 (ru) 2002-02-28
IL144289A0 (en) 2002-05-23
SK9972001A3 (en) 2002-03-05
PL349348A1 (en) 2002-07-15
HUP0202932A3 (en) 2003-07-28
WO2000042045A3 (en) 2000-11-09
CA2372197A1 (en) 2000-07-20
BR9916905A (pt) 2002-01-29
HUP0202932A2 (hu) 2002-12-28
ZA200106592B (en) 2002-08-12

Similar Documents

Publication Publication Date Title
CN1344270A (zh) 作为趋化因子受体调节剂的官能化杂环
CN1192021C (zh) 作为阿片受体配体的3-氮杂二环[3.1.0]己烷衍生物
CN1290846C (zh) 吡唑并[1,5-a]吡啶化合物及其药物
CN1230431C (zh) 用作类胰蛋白酶抑制剂的芳基甲胺衍生物
CN1046724C (zh) 吡唑并吡啶化合物、含有它们的药物组合物、及其制法与用途
CN1202108C (zh) 螺环化合物,制备方法及中间体
CN1274690C (zh) 三杂环化合物和包括其作为活性组分的药物
CN1069624C (zh) 4a,5,9,10,11,12-六氢-6H-苯并呋喃并[3a,3,2-ef][2]苯并吖庚因衍生物的制备方法
CN1179960C (zh) 吲哚衍生物和其在治疗骨质疏松中的应用以及其它应用
CN1930160A (zh) Hiv整合酶抑制剂
CN1071917A (zh) 用作人类免疫缺陷病毒逆转录酶拮抗剂的喹唑啉衍生物
CN1106003A (zh) 微粒体甘油三酯转移蛋白的抑制剂和方法
CN1173867A (zh) 吲哚基神经肽y受体拮抗剂
CN1361100A (zh) 新的杂环衍生物及其医药用途
CN1756746A (zh) 作为阿片样物质受体拮抗剂的6-取代的烟酰胺衍生物
CN1137273A (zh) 喹嗪酮类化合物
CN101068545A (zh) 作为β-分泌酶抑制剂用于治疗阿尔茨海默病的螺哌啶化合物
CN1444570A (zh) 非甾体抗炎药
CN1483024A (zh) Vla-4抑制剂
CN1209803A (zh) 微粒体甘油三酯转移蛋白的构象限制性芳族抑制剂及方法
TW201307314A (zh) 作為ep4受體拮抗劑之吡啶醯胺衍生物
CN1501932A (zh) 作为保胎用催产素受体拮抗剂的三环二氮杂�
CN1030701C (zh) 吲哚衍生物的制备方法
CN1064042C (zh) 苯并吖庚因衍生物的中间体
CN1285834A (zh) 稠合吡嗪化合物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1044539

Country of ref document: HK